Xencor Presents Findings on New Aspect of its Fc Technology Targeting Autoimmune Disease Monrovia, Calif. — December 7, 2007 — Xencor, Inc., a company developing protein and antibody therapeutics, presented findings at IBC Life Sciences’ 17th Annual Antibody Engineering Conference demonstrating the

- 12 of 15 (80%) patients completed the study and achieved the primary endpoint of at least a two-point reduction in the IgG4-RD Responder Index on Day 169 -- Eight patients achieved remission (IgG4-RD RI of zero) -- XmAb5871 well tolerated in patients with active IgG4-RD -

MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 10, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of data from the first patients in the

Investigational New Drug (IND) application filing for XmAb5871 in IgG4-Related Disease expected before year's end

Xencor Presents Data from Pre-clinical Studies of its Anti-CD19 and Anti-CD40 Antibodies at the 50th Annual Meeting of the American Society of Hematology Monrovia, Calif. – December 9, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, presented results Sunday at the 50th

MONROVIA, Calif. --(BUSINESS WIRE)--Dec. 12, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced additional clinical data from expansion cohorts in its

MONROVIA, Calif. --(BUSINESS WIRE)--Dec. 12, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced updated data from its Phase 1 dose-escalation

MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 8, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from its preclinical-stage

MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 12, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple

MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 9, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple preclinical XmAb ®